ARRHYTHMOGENIC CARDIOMYOPATHY
Clinical trials for ARRHYTHMOGENIC CARDIOMYOPATHY explained in plain language.
Never miss a new study
Get alerted when new ARRHYTHMOGENIC CARDIOMYOPATHY trials appear
Sign up with your email to follow new studies for ARRHYTHMOGENIC CARDIOMYOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene therapy for rare heart disease passes early safety check
Disease control ENROLLING_BY_INVITATIONThis study follows 10 people who already received LX2020 gene therapy for arrhythmogenic cardiomyopathy caused by a PKP2 gene mutation. Researchers will monitor them for years to see if the treatment remains safe and continues to help control the disease. The goal is to understan…
Matched conditions: ARRHYTHMOGENIC CARDIOMYOPATHY
Sponsor: Lexeo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Gene therapy trial targets rare heart disease in 10 patients
Disease control OngoingThis early-stage trial tests a gene therapy called LX2020 for people with a heart condition called arrhythmogenic cardiomyopathy, caused by a change in the PKP2 gene. The study involves 10 adults who already have a defibrillator implanted. The main goal is to see if the treatment…
Matched conditions: ARRHYTHMOGENIC CARDIOMYOPATHY
Phase: PHASE1, PHASE2 • Sponsor: Lexeo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC